• xxx

NAIDOO, Dr Jarushka

Dr. Jarushka Naidoo is a Consultant Medical Oncologist at Beaumont RCSI Cancer Centre in Dublin, Ireland; and an Adjunct Assistant Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center and Bloomberg-Kimmel Center for Cancer Immunotherapy, at Johns Hopkins University.

Dr. Naidoo graduated with her medical degree (MB BCh BAO) from Trinity College Dublin, and completed both internal medicine training and a medical oncology fellowship through the Royal College of Physicians of Ireland. She then completed an awarded advanced fellowship at Memorial Sloan Kettering Cancer Center (New York), and joined the faculty at Johns Hopkins University in 2015. At Johns Hopkins, she led a portfolio of clinical trials and translational studies focused on immunotherapy for lung cancer and immune-related toxicity. She founded and co-chaired the multidisciplinary Johns Hopkins Immune-related Toxicity Team since 2016. Dr. Naidoo currently leads investigator-initiated trials for patients with lung cancer, specifically for those with stage III non-small lung cancer, and those with CNS metastases. She is a leader in the field of immune-related toxicity, having published the first comprehensive analysis of immune-related pneumonitis (Best of J Clin Oncol 2017), bullous pemphigoid (Best of Cancer Immunol Res 2016), and inflammatory arthritis (Ann Rheum Dis 2016). She is the Chair of the Immunotherapy Subcommittee of the US NRG Clinical Trials Cooperative Group, and develops the ASCO, NCCN and SITC Immune-Related Toxicity Guideline Panels. She is the recipient of several grants and awards including a US NIH KL2 Clinical Scholar Award, and a Lung Cancer Foundation of America/IASLC Young Investigator Award on biomarkers of immunotherapy response and toxicity.

Since her return to Ireland (October 2020), she serves as the Chair of the Lung Cancer Disease-specific subgroup (DSSG) of Cancer Trials Ireland, is the Founder and Chair of the Irish national lung cancer research group, the ‘Irish Lung Cancer Alliance,’ and is the recipient of the Irish Cancer Society’s Clinician Research Leader Award 2021

UK Oncology Forum 2024

The UK Oncology Forum is only open to UK healthcare professionals. By choosing to continue to enter the UK Oncology Forum website, you are confirming that you are a UK healthcare professional.